Title of Dataset: Cohesin_mutations_in_acute_myeloid_leukemia_data

Patients with acute myeloid leukemia (AML) from previously reported
multicenter trials: AML96 [NCT00180115], AML2003 [NCT00180102],
AML60+ [NCT 00180167], SORAML [NCT00893373] Pre-treatment peripheral
blood or bone marrow aspirates were screened for genetic alterations
using next-generation sequencing (NGS)

Results: We identified distinct co-mutational patters for mutations of
STAG2, which were associated with normal karyotypes (NK) and concomitant
mutations in IDH2, RUNX1, BCOR, ASXL1, and SRSF2. Mutated RAD21 was
associated with NK, mutated EZH2, KRAS, CBL, and NPM1. We found almost
complete mutual exclusivity of genetic alterations of individual cohesin
subunits. Conclusion: This mutual exclusivity may be the basis for
therapeutic strategies via synthetic lethality in cohesin mutated AML.

Data description: Cohesin mutation status is displayed differentiating
between RAD21, STAG2, SMC3, SMC1A p.HGVS codes are used to denote
specific alterations presence (1) or absence (0) of a feature is
reported European Leukemia Net 2022 (ELN2022) risk stratification
(Döhner et al., Blood 2022) was used.

Further information on clinical trial protocols can be obtained from
www.clinicaltrials.gov using the following identifiers: NCT00180115,
NCT00180102, NCT 00180167, SORAML NCT00893373